市場調査レポート

癌治療の世界市場:モノクロナール抗体・チロシンキナーゼ阻害剤・癌ワクチン・サイトカイン・遺伝子療法・従来型化学療法

The World Market for Cancer Therapeutics (Monoclonal Antibodies, TKIs, Vaccines, Cytokines, Gene Therapy, Chemotherapy, Others), Phase I - III Pipeline Analysis, Markets by Segment

発行 Kalorama Information 商品コード 217057
出版日 ページ情報 英文 320 Pages
即納可能
価格
本日の銀行送金レート: 1USD=104.18円で換算しております。
Back to Top
癌治療の世界市場:モノクロナール抗体・チロシンキナーゼ阻害剤・癌ワクチン・サイトカイン・遺伝子療法・従来型化学療法 The World Market for Cancer Therapeutics (Monoclonal Antibodies, TKIs, Vaccines, Cytokines, Gene Therapy, Chemotherapy, Others), Phase I - III Pipeline Analysis, Markets by Segment
出版日: 2015年11月12日 ページ情報: 英文 320 Pages
概要

世界では3,500万人から4,000万人の人々が癌を患っており、年間約800万人が癌で亡くなっています。最も一般的な癌は、肺癌、乳癌、結腸/直腸癌、胃癌、肝臓癌、前立腺癌、子宮頸癌、食道癌および膀胱癌です。先進国における癌患者の死亡率は約50%ですが、これは新興諸国における癌患者の死亡率が約80%であるのとは対照的です。

当レポートでは、世界の癌治療市場について調査し、市場の成長促進因子と抑制因子、新しい治療法・従来型治療法の市場推計と予測、主な製品の収益と市場シェア、製品別の市場分析、癌の種類・治療法の分類 (新規・従来型) 別による市場規模・推計、開発段階別 (フェーズI・フェーズII・フェーズIII) の市場分析、および主要企業のプロファイルなどをまとめ、お届けいたします。

第1章 エグゼクティブサマリー

第2章 イントロダクション、新しいアプローチおよび従来のアプローチ

  • 癌とは
  • 癌細胞の生化学
  • 発癌物質の代謝
  • 癌増殖の原因
  • 癌治療市場の歴史と成長
  • オーダーメイド医療はどのように癌市場を変化させるのか
  • 標的癌療法
  • 癌における遺伝子検査
  • 産業構造
  • 癌治療のアプローチ:従来型 vs. 新規
  • 製品の例
  • モノクロナール抗体
  • チロシンキナーゼ阻害剤
  • 癌ワクチン
  • サイトカイン
  • 遺伝子治療
  • その他の新しい分類

第3章 市場促進因子/障壁

  • 世界における癌の影響
  • 寿命と癌
  • 米国:癌の実質費用
  • 癌の治療:最終目標
  • 癌治療のコスト
  • Healthy People 2020 (米国民の健康10年指針)
  • マーケティング・流通の動向
  • 高齢者の臨床試験への参加
  • 開発リスク
  • 新しい癌治療研究における開発リスク:アロベクチン-7
  • 開発プログラム
  • 新しい治療法開発のパイプラントはどのようなものか?
  • 近年のNDA活動
  • 新たな指標
  • 市場参入:規制が認可および優先審査を加速
  • 開発・マーケティング合意
  • 保険・医療費償還の問題

第4章 膀胱癌の治療における新たな治療法

  • 膀胱癌の概要
  • 発症・死亡の動向
  • 膀胱癌の治療
  • 新しい治療の開発活動
  • 開発企業の参加
  • 膀胱癌治療市場および機械
  • 新しい治療の展望

第5章 脳腫瘍の治療における新たな治療法

第6章 乳癌の治療における新たな治療法

第7章 大腸癌の治療における新たな治療法

第8章 腎臓癌の治療における新たな治療法

第9章 白血病の治療における新たな治療法

第10章 肝臓癌の治療における新たな治療法

第11章 肺癌の治療における新たな治療法

第12章 リンパ腫の治療における新たな治療法

第13章 メラノーマの治療における新たな治療法

第14章 多発性骨髄腫の治療における新たな治療法

第15章 膵臓癌の治療における新たな治療法

第16章 前立腺癌の治療における新たな治療法

第17章 新しい癌療法:市場サマリー

第18章 市場参入企業・主な開発企業

情報ソース

図表リスト

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: KLI5752001

Title: The World Market for Cancer Therapeutics by Product (Monoclonal Antibodies, Tyrosine Kinase, Inhibitors, Cancer Vaccines, Cytokines, Gene Therapy, Traditional Chemotherapy), by Cancer Type (Lung, Breast, Prostate, Stomach, Liver, Cervical, Bladder, Lymphoma, Esophagel, Colon, Brain, Head&Neck, Others), by Classification (Novel, Traditional), by Development Stage (Phase I, Phase II, Phase III).

Despite the advances in cancer treatment, cancer continues to affect about 4 million people annually, generating a significant loss of life, financial burden and overall strain on the health industry. Traditional therapies have failed to provide adequate treatment for these patients, signifying a need for an alternative treatment plan. Compassionate use has been granted for several therapies in the past and this trend is likely to continue. This report, The World Market for Cancer Therapeutics weaves these trends together into a detailed analysis of the market for treatments for cancer with a special emphasis on novel treatments.

Market information in the report includes:

  • Cancer Market Drivers and Barriers
  • Market Estimates and Forecasts for Novel Therapies and Traditional Treatments
  • Specific Product Revenues and Market Share
  • Market Analysis by Product (Monoclonal Antibodies, Tyrosine Kinase, Inhibitors, Cancer Vaccines, Cytokines, Gene Therapy, Traditional Chemotherapy),
  • Market Size and Estimate by Cancer Type (Lung, Breast, Prostate, Stomach, Liver, Cervical, Bladder, Lymphoma, Esophagel, Colon, Brain, Head&Neck, Others), by Classification (Novel, Traditional),
  • Market Analysis by Development Stage (Phase I, Phase II, Phase III)
  • Corporate Profiles
  • Analyst Conclusions

Worldwide between 35 and 40 million people are living with cancer and nearly 8 million people lose the battle annually. The most common cancers affecting the world population include lung, breast, colon/rectum, stomach, liver, prostate, cervical, esophageal, and bladder. Cancer deaths occur in about 50% of people who develop cancer in developed countries; this is in contrast to 80% death rate in cancer patients in underdeveloped countries.

The mainstay of systemic therapy for solid and hematological malignancies in the 20th century was chemotherapy. This approach has drawbacks including toxicity to normal tissue, drug resistance and lack of efficacy. The demand for more effective and tolerable treatments has led to the development of novel therapeutic agents that specifically target the malignant cells.

The report includes statistical information for cancers by type worldwide. Specifically, cancers where there are current products available or are in development and/or have significant incidence/mortality rates are profiled. The market segments provide an overview of disease epidemiology, leading product sales, market estimates and forecasts, and competitive summary of leading providers. The report also includes several discussions on novel therapies in development and their impact on the market. Throughout the report, several market indicators, trends and barriers are discussed.

Information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company reports and literature; government documents and databases; research journals and reports; and general medical and business journals.

Secondary research was used to determine market size for cancer types by product sales. In instances where multiple cancers are treated with one product, a formula was used to determine distribution of sales. This included incidence and mortality rates of each cancer, typical treatment regimen, cost of individual therapy and other factors. Billing databases and pricing charts were the primary sources of information, followed by interviews to verify initial findings.

Primary research methods included telephone interviews and email correspondence with company representatives, researchers, government representatives, and physicians. These interviews were conducted with the purpose of capturing the perspectives from industry participants on the market opportunity and current trends. This was the basis of formulating forecast models and for confirming early findings related to market potential.

Companies Profiled Include:

  • AbbVie
  • Acerta Pharma
  • Adaptimmune
  • Advantagene
  • Altor BioScience
  • Amge
  • Apceth GmbH & Co. KG
  • Array BioPharma
  • Astex Pharmaceuticals
  • AstraZeneca plc
  • Bayer
  • Bellicum Pharmaceuticals, Inc.
  • BioCancell Ltd.
  • Bluebird Bio
  • Boehringer Ingelheim
  • Boston Biomedical
  • Bristol-Myers Squibb Company
  • Caladrius (NeoStem)
  • Celgene
  • Celldex Therapeutics
  • Celsion Corporation
  • Clovis Oncology
  • Cold Genesys, Inc
  • Daiichi Sankyo
  • Eisai
  • Eli Lilly & Company
  • EMD Serono
  • Galena Biopharma
  • Gamida Cell
  • Genprex, Inc.
  • Gilead Sciences
  • Immunomedics
  • Incyte
  • Inovio
  • Johnson & Johnson
  • Juno Therapeutics
  • Karyopharm Therapeutics
  • MaxiVAX 3
  • MedImmune
  • Merck & Company
  • Millennium (Takeda Oncology)
  • Momotaro-Gene, Inc.
  • MultiVir, Inc.
  • Northwest Biotherapeutics
  • Novartis
  • Oncolytics Biotech
  • OncoMed
  • OncoSec Medical, Inc.
  • Pfizer, Inc.
  • Roche
  • Sanofi
  • Seattle Genetics
  • Sevion Therapeutics
  • Takara Bio
  • Tocagen
  • VBL Therapeutics
  • ZIOPHARM Oncology, Inc.

Table of Contents

ONE: EXECUTIVE SUMMARY

  • Introduction
  • Scope and Methodology
  • Size and Growth of the Market

TWO: INTRODUCTION, NOVEL AND TRADITIONAL APPROACHES

  • What is Cancer
  • Biochemistry of Cancer Cells
  • Carcinogen Metabolism
  • Causes of Cancer Growth
  • History and Growth of the Cancer Treatment Market
  • How Personalized Medicine is Changing the Cancer Market
  • Targeted Cancer Therapy
  • Genetic Testing in Cancer
  • Industry Structure
  • Cancer Treatment Approaches: Traditional vs. Novel
  • Product Examples
  • Monoclonal Antibodies
  • Tyrosine Kinase Inhibitors
  • Cancer Vaccines
  • Cytokines
  • Gene Therapy
  • Other Novel Classifications

THREE: MARKET DRIVERS / BARRIERS

  • Global Cancer Impact
  • Life Expectancy and Cancer
  • The United States - The Real Cost of Cancer
  • Curing Cancer-The Ultimate Goal
  • The Cost of Cancer Therapies
  • Healthy People 2020
  • Marketing and Distribution Trends
  • Elderly Clinical Trial Involvement
  • Development Risk
  • Development Risk in Novel Cancer Therapy Research-Allovectin-7
  • Development Programs
  • What Does the Novel Therapy Development Pipeline Look Like?
  • Recent NDA Activity
  • New Indications
  • Reaching the Market: Regulatory Accelerated Approvals and Priority Reviews
  • Development and Marketing Agreements
  • Insurance and Reimbursement Issues

FOUR: NOVEL THERAPIES IN BLADDER CANCER TREATMENT

  • Bladder Cancer Overview
  • Trends in Incidence and Mortality
  • Treating Bladder Cancer
  • Novel Treatment Research Activities
  • Developer Participation
  • Bladder Cancer Treatment Market and Opportunity
  • Novel Treatment Outlook

FIVE: NOVEL THERAPIES IN BRAIN CANCER TREATMENT

  • Brain Cancer Overview
  • Trends in Incidence and Mortality
  • Treating Brain Cancer
  • Novel Treatment Research Activities
  • Developer Participation
  • Brain Cancer Treatment Market and Opportunity
  • Novel Treatment Outlook

SIX: NOVEL THERAPIES IN BREAST CANCER TREATMENT

  • Breast Cancer Overview
  • Trends in Incidence and Mortality
  • Treating Breast Cancer
  • Novel Treatment Research Activities
  • Developer Participation
  • Breast Cancer Treatment Market and Opportunity
  • Novel Treatment Outlook
  • Leading Products and Suppliers

SEVEN: NOVEL THERAPIES IN COLORECTAL CANCER TREATMENT115

  • Colorectal Cancer Overview
  • Trends in Incidence and Mortality
  • Treating Colorectal Cancer
  • Novel Treatment Research Activities
  • Developer Participation
  • Colorectal Cancer Treatment Market and Opportunity
  • Novel Treatment Outlook
  • Leading Products and Suppliers

EIGHT: NOVEL THERAPIES IN KIDNEY CANCER TREATMENT

  • Kidney Cancer Overview
  • Trends in Incidence and Mortality
  • Treating Kidney Cancer
  • Novel Treatment Research Activities
  • Developer Participation
  • Kidney Cancer Treatment Market and Opportunity
  • Novel Treatment Outlook
  • Leading Products and Suppliers

NINE: NOVEL THERAPIES IN LEUKEMIA TREATMENT

  • Leukemia Cancer Overview
  • Trends in Incidence and Mortality
  • Treating Leukemia
  • Novel Treatment Research Activities
  • Developer Participation
  • Leukemia Treatment Market and Opportunity
  • Novel Treatment Outlook
  • Leading Products and Suppliers

TEN: NOVEL THERAPIES IN LIVER CANCER TREATMENT

  • Liver Cancer Overview
  • Trends in Incidence and Mortality
  • Treating Liver Cancer
  • Novel Treatment Research Activities
  • Developer Participation
  • Liver Cancer Treatment Market and Opportunity
  • Novel Treatment Outlook

ELEVEN: NOVEL THERAPIES IN LUNG CANCER TREATMENT

  • Lung Cancer Overview
  • Trends in Incidence and Mortality
  • Treating Lung Cancer
  • Novel Treatment Research Activities
  • Developer Participation
  • Lung Cancer Treatment Market and Opportunity
  • Novel Treatment Outlook
  • Leading Products and Suppliers

TWELVE: NOVEL THERAPIES IN LYMPHOMA TREATMENT

  • Lymphoma Overview
  • Trends in Incidence and Mortality
  • Treating Lymphoma
  • Novel Treatment Research Activities
  • Developer Participation
  • Lymphoma Treatment Market and Opportunity
  • Novel Treatment Outlook
  • Leading Products and Suppliers
  • Figure 12-8

THIRTEEN: NOVEL THERAPIES IN MELANOMA TREATMENT

  • Melanoma Overview
  • Trends in Incidence and Mortality
  • Treating Melanoma
  • Novel Treatment Research Activities
  • Developer Participation
  • Melanoma Treatment Market and Opportunity
  • Novel Treatment Outlook
  • Leading Products and Suppliers

FOURTEEN: NOVEL THERAPIES IN MULTIPLE MYELOMA TREATMENT

  • Myeloma Overview
  • Trends in Incidence and Mortality
  • Treating Multiple Myeloma
  • Novel Treatment Research Activities
  • Developer Participation
  • Multiple Myeloma Treatment Market and Opportunity
  • Novel Treatment Outlook
  • Leading Products and Suppliers

FIFTEEN: NOVEL THERAPIES IN PANCREATIC CANCER TREATMENT229

  • Pancreatic Cancer Overview
  • Trends in Incidence and Mortality
  • Treating Pancreatic Cancer
  • Novel Treatment Research Activities
  • Developer Participation
  • Pancreatic Cancer Treatment Market and Opportunity
  • Novel Treatment Outlook and Suppliers' Market Impact

SIXTEEN: NOVEL THERAPIES IN PROSTATE CANCER TREATMENT 239

  • Prostate Cancer Overview
  • Trends in Incidence and Mortality
  • Treating Prostate Cancer
  • Novel Treatment Research Activities
  • Developer Participation
  • Prostate Cancer Treatment Market and Opportunity
  • Novel Treatment Outlook and Suppliers' Market Impact

SEVENTEEN: NOVEL CANCER THERAPIES: MARKET SUMMARY

  • Overview
  • How Have Novel Therapies Shaped the Market and What's In store for the Future?252
  • Novel Therapies and its Impact on Individual Cancer Markets
  • Geographical Market and Trends
  • Competitive Landscape

EIGHTEEN: MARKET PARTICIPANTS AND KEY DEVELOPERS

  • Introduction
  • AbbVie
  • Acerta Pharma
  • Adaptimmune
  • Advantagene
  • Altor BioScience
  • Amgen
  • Apceth GmbH & Co. KG
  • Array BioPharma
  • Astex Pharmaceuticals
  • AstraZeneca plc
  • Bayer
  • Bellicum Pharmaceuticals, Inc.
  • BioCancell Ltd.
  • Bluebird Bio
  • Boehringer Ingelheim
  • Boston Biomedical
  • Bristol-Myers Squibb Company
  • Caladrius (NeoStem)
  • Celgene
  • Celldex Therapeutics
  • Celsion Corporation
  • Clovis Oncology
  • Cold Genesys, Inc.
  • Daiichi Sankyo
  • Eisai
  • Eli Lilly & Company
  • EMD Serono
  • Galena Biopharma
  • Gamida Cell
  • Genprex, Inc.
  • Gilead Sciences
  • Immunomedics
  • Incyte
  • Inovio
  • Johnson & Johnson
  • Juno Therapeutics
  • Karyopharm Therapeutics
  • MaxiVAX
  • MedImmune
  • Merck & Company
  • Millennium (Takeda Oncology)
  • Momotaro-Gene, Inc.
  • MultiVir, Inc.
  • Northwest Biotherapeutics
  • Novartis
  • Oncolytics Biotech
  • OncoMed
  • OncoSec Medical, Inc.
  • Pfizer, Inc.
  • Roche
  • Sanofi
  • Seattle Genetics
  • Sevion Therapeutics
  • Takara Bio
  • Tocagen
  • VBL Therapeutics
  • ZIOPHARM Oncology, Inc.

INFORMATION SOURCES

LIST OF EXHIBITS

ONE: EXECUTIVE SUMMARY

  • Figure 1-1: Cancer Therapeutics Market, 2010-2020
  • Table 1-1: Novel Cancer Therapies Market, 2010-2020
  • Figure 1-2: Novel Cancer Therapies Market, 2010-2020

TWO: CANCER INDUSTRY DEVELOPMENT

  • Table 2-1: Viruses Associated with Cancer in Humans
  • Figure 2-1: Approved Cancer Therapies in the United States by Primary Indication
  • Figure 2-2: Market Value for Traditional vs. Novel Cancer Therapies
  • Figure 2-3: Market Distribution: Traditional vs. Novel Cancer
  • Figure 2-4: Leading Chemotherapy Treatments by 2015 Estimated Sales
  • Figure 2-5: Leading Hormone Cancer Treatments by 2015 Estimated Sales
  • Figure 2-6: Antibody Conjugates in Development by Phase
  • Figure 2-7: Antibody Conjugates in Development by Cancer Type

THREE: MARKET DRIVERS / BARRIERS

  • Table 3-1: Global Cancer Incidence by Selected Types of Cancer, 2012 and 2025, all races, all ages, both genders
  • Figure 3-1: Estimated and Projected Global Cancer Incidence by Selected Types of Cancer, 2012 and 2025
  • Table 3-2: Most Common Cancer by Region and Gender
  • Table 3-3: Five-year Net Survival Rates* (%) for Selected Cancers among Adults 15 Years of Age and Older in Select Countries, Average 2005-2009
  • Figure 3-2: United States Average Years of Life Lost Per Person Dying of Cancer, All Races, Both Sexes, 2009
  • Figure 3-3: United States Estimated Person-Years of Life Lost Due to Cancer, All Races, Both Sexes, 2009
  • Figure 3-4: Novel Cancer Compounds in Development by Phase of Development
  • Figure 3-5: Novel Therapy Developments by Cancer Type
  • Figure 3-6: Phase III: Novel Cancer Compounds in Development for Major Indications, Distribution Estimates
  • Figure 3-7: Phase II: Novel Cancer Compounds in Development for Major Indications, Distribution Estimates
  • Figure 3-8: Phase I: Novel Cancer Compounds in Development for Major Indications, Distribution Estimates
  • Table 3-4: Select NDA Activity: 2015
  • Table 3-5: Select New Indications, 2015

FOUR: NOVEL THERAPIES IN BLADDER CANCER TREATMENT

  • Figure 4-1: Global Incidence and Mortality of Bladder Cancer by Country, 2012
  • Figure 4-2: Research Activities in Novel Bladder Cancer Treatment by Classification
  • Figure 4-3: Bladder Cancer Potential Targeted/Novel Therapies Development Pipeline by Phase of Development
  • Figure 4-4: Global Bladder Cancer Treatment Market, 2010-2020
  • Figure 4-5: Distribution of Sales by Broad Classification: Bladder Cancer Treatments, 2015
  • Figure 4-6: Novel Treatments for Bladder Cancer by Drug Classification, 2010-2020

FIVE: NOVEL THERAPIES IN BRAIN CANCER TREATMENT

  • Figure 5-1: Global Incidence and Mortality of Brain Cancer by Country, 2012
  • Figure 5-2: Research Activities in Novel Brain Cancer Treatment by Classification
  • Figure 5-3: Brain Cancer Potential Targeted/Novel Therapies Development Pipeline by Phase of Development
  • Figure 5-4: Global Brain Cancer Treatment Market, 2010-2020
  • Figure 5-5: Distribution of Sales by Broad Classification: Brain Cancer Treatments, 2015
  • Figure 5-6: Novel Treatments for Brain Cancer by Drug Classification, 2010-2020

SIX: NOVEL THERAPIES IN BREAST CANCER TREATMENT

  • Figure 6-1: Global Incidence and Mortality of Breast Cancer by Country, 2012
  • Figure 6-2: Research Activities in Novel Breast Cancer Treatment by Classification
  • Figure 6-3: Breast Cancer Potential Targeted/Novel Therapies Development Pipeline by Phase of Development
  • Figure 6-4: Global Breast Cancer Treatment Market, 2010-2020
  • Figure 6-5: Distribution of Sales by Broad Classification: Breast Cancer Treatments, 2015
  • Figure 6-6: Novel Treatments for Breast Cancer by Drug Classification, 2010-2020
  • Figure 6-7: Leading Novel Products in Breast Cancer Treatment based on Revenues, 2010-2015 111
  • Figure 6-8: Leading Novel Products in Breast Cancer Treatment based on Revenues, Market Share, Estimated 2015
  • Figure 6-9: Breast Cancer Novel Therapies: Leading Suppliers Shares by Market Revenues, Estimated 2015

SEVEN: NOVEL THERAPIES IN COLORECTAL CANCER TREATMENT

  • Figure 7-1: Global Incidence and Mortality of Colorectal Cancer by Country, 2012
  • Figure 7-2: Research Activities in Novel Colorectal Cancer Treatment by Classification
  • Figure 7-3: Colorectal Cancer Potential Targeted/Novel Therapies Development Pipeline by Phase of Development
  • Figure 7-4: Global Colorectal Cancer Treatment Market, 2010-2020
  • Figure 7-5: Distribution of Sales by Broad Classification: Colorectal Cancer Treatments, 2015
  • Figure 7-6: Novel Treatments for Colorectal Cancer by Drug Classification, 2010-2020
  • Table 7-7: Leading Novel Products in Colorectal Cancer Treatment based on Revenues, 2010-2015126
  • Figure 7-8: Leading Novel Products in Colorectal Cancer Treatment based on Revenues, Market Share, Estimated 2015
  • Figure 7-9: Colorectal Cancer Novel Therapies: Leading Suppliers Shares by Market Revenues, Estimated 2015

EIGHT: NOVEL THERAPIES IN KIDNEY CANCER TREATMENT

  • Figure 8-1: Global Incidence and Mortality of Kidney Cancer by Country, 2012
  • Figure 8-2: Research Activities in Novel Kidney Cancer Treatment by Classification
  • Figure 8-3: Kidney Cancer Potential Targeted/Novel Therapies Development Pipeline by Phase of Development
  • Figure 8-4: Global Kidney Cancer Treatment Market, 2010-2020
  • Figure 8-5: Distribution of Sales by Broad Classification: Kidney Cancer Treatments, 2015
  • Figure 8-6: Novel Treatments for Kidney Cancer by Drug Classification, 2010-2020
  • Table 8-7: Leading Novel Products in Kidney Cancer Treatment based on Revenues, 2010-2015138
  • Figure 8-8: Leading Novel Products in Kidney Cancer Treatment based on Revenues, Market Share, Estimated 2015
  • Figure 8-9: Kidney Cancer Novel Therapies: Leading Suppliers Shares by Market Revenues, Estimated 2015

NINE: NOVEL THERAPIES IN LEUKEMIA TREATMENT

  • Table 9-1: Leukemia Overview by Type
  • Figure 9-1: Distribution of Leukemia Cases by Type
  • Figure 9-2: Global Incidence and Mortality of Leukemia by Country, 2012
  • Figure 9-3: Research Activities in Novel Leukemia Treatment by Classification
  • Figure 9-4: Leukemia Potential Targeted/Novel Therapies Development Pipeline by Phase of Development
  • Figure 9-5: Global Leukemia Treatment Market, 2010-2020
  • Figure 9-6: Distribution of Sales by Broad Classification: Leukemia Treatments, 2015
  • Figure 9-7: Novel Treatments for Leukemia by Drug Classification, 2010-2020
  • Figure 9-8: Leading Novel Products in Leukemia Treatment based on Revenues, 2010-2015
  • Figure 9-9: Leading Novel Products in Leukemia Treatment based on Revenues, Market Share, Estimated 2015
  • Figure 9-10: Leukemia Novel Therapies: Leading Suppliers Shares by Market Revenues, Estimated 2015

TEN: NOVEL THERAPIES IN LIVER CANCER TREATMENT

  • Figure 10-1: Global Incidence and Mortality of Liver Cancer by Country, 2012
  • Figure 10-2: Research Activities in Novel Liver Cancer Treatment by Classification
  • Figure 10-3: Liver Cancer Potential Targeted/Novel Therapies Development Pipeline by Phase of Development
  • Figure 10-4: Global Liver Cancer Treatment Market, 2010-2020
  • Figure 10-5: Distribution of Sales by Broad Classification: Liver Cancer Treatments, 2015

ELEVEN: NOVEL THERAPIES IN LUNG CANCER TREATMENT

  • Table 11-1: Types of Primary Lung Cancer
  • Figure 11-1: Global Incidence and Mortality of Lung Cancer by Country, 2012
  • Figure 11-2: Research Activities in Novel Lung Cancer Treatment by Classification
  • Figure 11-3: Lung Cancer Potential Targeted/Novel Therapies Development Pipeline by Phase of Development
  • Figure 11-4: Global Lung Cancer Treatment Market, 2010-2020
  • Figure 11-5: Distribution of Sales by Broad Classification: Lung Cancer Treatments, 2015
  • Figure 11-6: Novel Treatments for Lung Cancer by Drug Classification, 2010-2020
  • Figure 11-7: Leading Novel Products in Lung Cancer Treatment based on Revenues, 2010-2015.. 181
  • Figure 11-8: Leading Novel Products in Lung Cancer Treatment based on Revenues, Market Share, Estimated 2015
  • Figure 11-9: Lung Cancer Novel Therapies: Leading Suppliers Shares by Market Revenues, Estimated 2015

TWELVE: NOVEL THERAPIES IN LYMPHOMA TREATMENT

  • Table 12-1: Classification of Non-Hodgkin's Lymphomas
  • Figure 12-1: Global Incidence and Mortality of Lymphoma by Country, 2012
  • Figure 12-2: Research Activities in Novel Lymphoma Treatment by Classification
  • Figure 12-3: Lymphoma Potential Targeted/Novel Therapies Development Pipeline by Phase of Development
  • Figure 12-4: Global Lymphoma Treatment Market, 2010-2020
  • Figure 12-5: Distribution of Sales by Broad Classification: Lymphoma Treatments, 2015
  • Figure 12-6: Novel Treatments for Lymphoma by Drug Classification, 2010-2020
  • Figure 12-7: Leading Novel Products in Lymphoma Treatment based on Revenues, 2010-2015
  • Lymphoma Novel Therapies: Leading Suppliers Shares by Market Revenues, Estimated 2015

THIRTEEN: NOVEL THERAPIES IN MELANOMA TREATMENT

  • Table 13-1: Malignant Conditions of the Skin
  • Figure 13-1: Global Incidence and Mortality of Melanoma by Country, 2012
  • Figure 13-2: Research Activities in Novel Melanoma Treatment by Classification
  • Figure 13-3: Melanoma Potential Targeted/Novel Therapies Development Pipeline by Phase of Development
  • Figure 13-4: Global Melanoma Treatment Market, 2010-2020
  • Figure 13-5: Distribution of Sales by Broad Classification: Melanoma Treatments, 2015
  • Figure 13-6: Novel Treatments for Melanoma by Drug Classification, 2010-2020
  • Figure 13-7: Leading Novel Products in Melanoma Treatment based on Revenues, 2010-2015
  • Figure 13-8: Leading Novel Products in Melanoma Treatment based on Revenues, Market Share, Estimated 2015
  • Figure 13-9: Melanoma Novel Therapies: Leading Suppliers Shares by Market Revenues, Estimated 2015

FOURTEEN: NOVEL THERAPIES IN MULTIPLE MYELOMA TREATMENT

  • Figure 14-1: Global Incidence and Mortality of Multiple Myeloma by Country, 2012
  • Figure 14-2: Research Activities in Novel Multiple Myeloma Treatment by Classification
  • Figure 14-3: Multiple Myeloma Potential Targeted/Novel Therapies Development Pipeline by Phase of Development
  • Figure 14-4: Global Multiple Myeloma Treatment Market, 2010-2020
  • Figure 14-5: Distribution of Sales by Broad Classification: Multiple Myeloma Treatments, 2015 .. 223
  • Figure 14-6: Novel Treatments for Multiple Myeloma by Drug Classification, 2010-2020
  • Table 14-7: Leading Novel Products in Multiple Myeloma Treatment based on Revenues, 2010- 2015
  • Figure 14-8: Multiple Myeloma Novel Therapies: Leading Suppliers Shares by Market Revenues, Estimated 2015

FIFTEEN; NOVEL THERAPIES IN PANCREATIC CANCER TREATMENT229

  • Figure 15-1: Global Incidence and Mortality of Pancreatic Cancer by Country, 2012
  • Figure 15-2: Research Activities in Novel Pancreatic Cancer Treatment by Classification
  • Figure 15-3: Pancreatic Cancer Potential Targeted/Novel Therapies Development Pipeline by Phase of Development
  • Figure 15-4: Global Pancreatic Cancer Treatment Market, 2010-2020
  • Figure 15-5: Distribution of Sales by Broad Classification: Pancreatic Cancer Treatments, 2015
  • Figure 15-6: Novel Treatments for Pancreatic Cancer by Drug Classification, 2010-2020
  • SIXTEEN: NOVEL THERAPIES IN PROSTATE CANCER TREATMENT 239
  • Figure 16-1: Global Incidence and Mortality of Prostate Cancer by Country, 2012
  • Figure 16-2: Research Activities in Novel Prostate Cancer Treatment by Classification
  • Figure 16-3: Prostate Cancer Potential Targeted/Novel Therapies Development Pipeline by Phase of Development
  • Figure 16-4: Global Prostate Cancer Treatment Market, 2010-2020
  • Figure 16-5: Distribution of Sales by Broad Classification: Prostate Cancer Treatments, 2015
  • Figure 16-6: Novel Treatments for Prostate Cancer by Drug Classification, 2010-2020

SEVENTEEN: NOVEL CANCER THERAPIES: MARKET SUMMARY

  • Table 17-1: Novel Cancer Therapies, Global Market Value by Classification, 2010-2020
  • Figure 17-1: Novel Cancer Therapies, Global Market Value by Classification, 2010-2020
  • Figure 17-2: Novel Cancer Therapies, Market Share by Classification of Treatment, 2015
  • Figure 17-3: Novel Therapy Potential by Cancer Type, 2015 and 2020 Estimates
  • Figure 17-4: Distribution of Novel Cancer Therapy Potential in Cancer, by Type, 2020
  • Figure 17-4: Novel Cancer Therapy Market by Broad Region, 2015 Estimated Distribution
  • Table 17-2: Novel Cancer Therapy Market, Leading Suppliers' Shares by Market Revenues, 2015263
  • Figure 17-5: Novel Cancer Therapy Market, Leading Suppliers' Market Share, 2015

EIGHTEEN: MARKET PARTICIPANTS AND KEY DEVELOPERS

  • Figure 18-1: Novel Cancer Therapies in Development for Leading Companies

INFORMATION SOURCES

Back to Top